Long‐term safety and efficacy of rIX‐FP prophylaxis with extended dosing intervals up to 21 days in adults/adolescents with hemophilia B

BACKGROUND: An international, multicenter extension study evaluated recombinant fusion protein linking recombinant coagulation factor IX (FIX) with recombinant human albumin (rIX‐FP) in hemophilia B (FIX ≤ 2%) patients previously enrolled in a phase III study or who initiated rIX‐FP prophylaxis foll...

Descripción completa

Detalles Bibliográficos
Autores principales: Mancuso, Maria Elisa, Lubetsky, Aaron, Pan‐Petesch, Brigitte, Lissitchkov, Toshko, Nagao, Azusa, Seifert, Wilfried, Li, Yanyan, Santagostino, Elena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
HAEMOSTASIS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318213/
https://www.ncbi.nlm.nih.gov/pubmed/32078256
http://dx.doi.org/10.1111/jth.14778

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318213/
https://www.ncbi.nlm.nih.gov/pubmed/32078256
http://dx.doi.org/10.1111/jth.14778

Ejemplares similares